The Washington University SPORE in Leukemia is a highly dynamic translational cancer research program that focuses specifically on leukemias and myelodysplastic syndromes (MDS). We have assembled an outstanding group of investigators with complementary expertise in basic and clinical leukemia research. In this SPORE, we leverage expertise in cancer genomics, immunology, and hematopoiesis to develop innovative translational research in leukemia. Our long term goal is to develop novel biomarkers and treatments for leukemias and MDS and to recruit and promote innovative translational leukemia research. To achieve these goals, the following specific aims are proposed.
Aim 1. To exploit recent advances in cancer genomics to develop novel biomarkers and treatments for leukemias and MDS. Washington University has been at the forefront of genomic studies in AML and MDS. Through sequencing of primary acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) genomes, we identified several novel recurring mutations of genes involved in DNA methylation (DNMT3A and IDH1) and RNA splicing (U2AF1). This basic research has led to the development of the following two translational SPORE projects. Project 1. Molecular determinants of decitabine responsiveness Project 3. Development of RNA splicing modulators for myelodysplastic syndromes and AML.
Aim 2. To leverage local expertise in immunology and hematopoiesis to develop novel treatments for leukemias and myelodvsplastic syndromes. Institutional expertise in basic immunology and hematopoiesis research has led to the development of two innovative translational projects in leukemia. Project 2. Targeting the bone marrow microenvironment in acute lymphocytic leukemia. Project 4. Epigenetic modulation of graft versus host disease and graft versus leukemia.
Aim 3. To enhance the infrastructure that supports translational leukemia research. This SPORE will support the following Shared Research Resources: 1) Core A. Biospecimen Processing;2) Core B. Biostatistics;and 3) Core C. Administration.
Aim 4. To recruit and train new investigators in translational research.
Aim 5. To facilitate inter-SPORE collaboration.

Public Health Relevance

This SPORE will promote translational research in leukemia and myelodysplastic syndromes. The proposed studies will test novel approaches to treat patients with acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndromes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA171963-02
Application #
8729566
Study Section
Special Emphasis Panel (ZCA1-RPRB-0 (M1))
Program Officer
Nothwehr, Steven F
Project Start
2013-09-03
Project End
2018-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
2
Fiscal Year
2014
Total Cost
$1,379,998
Indirect Cost
$461,424
Name
Washington University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
White, Brian S; DiPersio, John F (2014) Genomic tools in acute myeloid leukemia: From the bench to the bedside. Cancer 120:1134-44
Mesa, Ruben A; Kiladjian, Jean-Jacques; Verstovsek, Srdan et al. (2014) Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica 99:292-8
Hopman, Rusudan K; DiPersio, John F (2014) Advances in stem cell mobilization. Blood Rev 28:31-40
Welch, John S (2014) Mutation position within evolutionary subclonal architecture in AML. Semin Hematol 51:273-81
Ramsingh, Giridharan; Westervelt, Peter; McBride, Ali et al. (2014) Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML. Int J Hematol 99:272-8
Giralt, Sergio; Costa, Luciano; Schriber, Jeffrey et al. (2014) Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations. Biol Blood Marrow Transplant 20:295-308
Anthony, Bryan A; Link, Daniel C (2014) Regulation of hematopoietic stem cells by bone marrow stromal cells. Trends Immunol 35:32-7
Welch, John S; Niu, Haixia; Uy, Geoffrey L et al. (2014) A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML. Am J Hematol 89:E103-8
Calvi, Laura M; Link, Daniel C (2014) Cellular complexity of the bone marrow hematopoietic stem cell niche. Calcif Tissue Int 94:112-24
Jacoby, Meagan A; Martin, Michael G; Uy, Geoffrey L et al. (2014) Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia. Am J Hematol 89:487-92

Showing the most recent 10 out of 12 publications